Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03482154 · ClinicalTrials.gov registry record
Malglycemia in the Pediatric Hematopoietic Stem Cell Transplant Population
A clinical trial, sponsored by University of Colorado, Denver.
- Completed
- Registry status
- 344
- Enrollment target
NCT03482154: Completed study, sponsored by University of Colorado, Denver.
NCT03482154 is a clinical trial that has completed, run by University of Colorado, Denver. The registered enrollment target is 344 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03482154 has completed, sponsored by University of Colorado, Denver.
- COMPLETED
- Registry status
- 344 participants
- Enrollment target
Study Summary
This is a retrospective chart review of patients who underwent a hematopoietic stem cell transplant (HSCT) between 1994 and 2016 to evaluate incidence of malglycemia and the relationship to specific outcomes.
Primary Outcome
hypoglycemia (BG \< 70 mg/dL), hyperglycemia (BG ≥ 126 mg/dL), or glycemic variability (σ ≥ 29 mg/dL)
Interventions
- PROCEDURE Hematopoietic Stem Cell Transplant
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 344 participants |
| Start Date | 2016-09-06 |
| Est. Completion | 2019-06-30 |
What the finished NCT03482154 record still lists
NCT03482154 is an observational study that tracks outcomes without assigning an intervention. The registered 344 participants enrollment target is mid-sized for trials with a published cap.
The record links to 0 conditions, and to 1 intervention - of which Hematopoietic Stem Cell Transplant is the first listed.
NCT03482154 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03482154 about?
NCT03482154 is a clinical study titled "Malglycemia in the Pediatric Hematopoietic Stem Cell Transplant Population". This is a retrospective chart review of patients who underwent a hematopoietic stem cell transplant (HSCT) between 1994 and 2016 to evaluate incidence of malglycemia and the relationship to specific outcomes.
What is the current status of trial NCT03482154?
This trial is currently completed. The enrollment target is 344 participants. The study started on 2016-09-06. Estimated completion is 2019-06-30.
What interventions are being tested in trial NCT03482154?
The interventions under investigation include: Hematopoietic Stem Cell Transplant (PROCEDURE).
Who is sponsoring clinical trial NCT03482154?
This trial is sponsored by University of Colorado, Denver, which has 1,283 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06733363 · 344 participants · Phase 2
A Cruciferous Vegetable Eating Program for the Reduction of Cancer Recurrence and Progression in Patients With Non-muscle Invasive Bladder Cancer
- NCT07179380 · 344 participants · Phase 3
Efficacy and Safety Study of Treprostinil Palmitil Inhalation Powder (TPIP) in Participants With Pulmonary Hypertension Associated With Interstitial Lung Disease (PH-ILD)
- NCT07304024 · 344 participants · Phase 1
A Treatment for a Form of Age-Related Central Auditory Processing Disorder Consisting of Clemastine Fumarate Plus Engineered Sound
- NCT03972657 · 345 participants · Phase 1
A Trial to Find Out if REGN5678 (Nezastomig) is Safe and How Well it Works Alone or in Combination With Cemiplimab for Adult Participants With Metastatic Castration-Resistant Prostate Cancer and Other Tumors
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI